

ABSTRACT

A low toxicity, stable oxazaphosphorine containing compositions with mesna for parenteral administration has been described. The process essentially requires addition of an oxazaphosphorine antineoplastic to the aqueous solution of an etherified  $\beta$ -cyclodextrin followed by addition of mesna as such or as an aqueous solution containing optionally, an etherified  $\beta$ -cyclodextrin. Preferably, the oxazaphosphorine antineoplastic is Ifosfamide and the etherified  $\beta$ -cyclodextrin is 2-hydroxypropyl- $\beta$ -cyclodextrin.

BEST AVAILABLE COPY